4-(5-Chloro-2-nitro-4-trifluoromethyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester | 474329-65-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(5-Chloro-2-nitro-4-trifluoromethyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
• 英文别名: Tert-butyl 4-[5-chloro-2-nitro-4-(trifluoromethyl)phenyl]piperazine-1-carboxylate
• CAS: 474329-65-2
• 化学式: C₁₆H₁₉ClF₃N₃O₄
• 分子量: 409.793
• InChiKey: LWAMABBVLXPCLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  27
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  78.6
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4-(5-Chloro-2-nitro-4-trifluoromethyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 在 lithium hydroxide 、 三乙酰氧基硼氢化钠 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 、 1,2-二氯乙烷 为溶剂， 反应 20.0h， 生成 1-{4-Nitro-2-trifluoromethyl-5-[4-(3-trifluoromethyl-benzyl)-piperazin-1-yl]-phenyl}-piperidine-4-carboxylic acid
  参考文献：
  名称：

  Synthesis and biological evaluation of piperazine-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)

  摘要：

  Compound 2 was identified by high throughput screening as a novel PAI-1 inhibitor. Systematic optimization of the A, B, and C segments of 2 resulted in the identification of a more potent compound 39 with good oral bioavailability. The synthesis and SAR data are presented in this report. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.035
• 作为产物：
  描述：

  2,4-二氯-5-硝基三氟甲基苯 、 N-Boc-哌嗪 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 生成 4-(5-Chloro-2-nitro-4-trifluoromethyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester
  参考文献：
  名称：

  Synthesis and biological evaluation of piperazine-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)

  摘要：

  Compound 2 was identified by high throughput screening as a novel PAI-1 inhibitor. Systematic optimization of the A, B, and C segments of 2 resulted in the identification of a more potent compound 39 with good oral bioavailability. The synthesis and SAR data are presented in this report. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.035

文献信息

• Inhibitors of bace
  申请人：——

  公开号：US20030095958A1

  公开（公告）日：2003-05-22

  The present invention relates to inhibitors of aspartic proteinases, particularly, BACE. The present invention also relates to compositions thereof and methods therewith for inhibiting BACE activity in a mammal, and for treating Alzheimer's Disease and other BACE-mediated diseases.

  本发明涉及天冬氨酸蛋白酶抑制剂，特别是BACE。本发明还涉及其组合物和方法，用于在哺乳动物中抑制BACE活性，并用于治疗阿尔茨海默病和其他BACE介导的疾病。
• [EN] SUBSTITUTED PIPERAZINE ANTITHROMBOTIC PAI-1 INHIBITORS<br/>[FR] INHIBITEURS ANTITHROMBOTIQUES DE PAI-1, A BASE DE PIPERAZINE SUBSTITUEE
  申请人：SCHERING AG

  公开号：WO2003080060A1

  公开（公告）日：2003-10-02

  This invention is directed to substituted piperazine compounds of formula (I) and their pharmaceutically acceptable salts which are useful as antithrombotic agents by inhibiting plasminogen activator inhibitor-1 (PAI-1). In addition, the present invention relates to pharmaceutical compositions and their pharmaceutically acceptable salts, containing the substituted piperazine compounds, derivatives of the substituted piperazine compounds, and methods of using the compounds to treat disease-states characterized by thrombotic activity.

  本发明涉及公式（I）的取代哌嗪化合物及其药学上可接受的盐，其通过抑制纤溶酶原激活剂抑制物-1（PAI-1）而用作抗血栓剂。此外，本发明涉及含有取代哌嗪化合物、取代哌嗪化合物衍生物的药物组合物及其药学上可接受的盐，以及使用这些化合物治疗以血栓形成活动为特征的疾病状态的方法。
• INHIBITORS OF BACE
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1389194A2

  公开（公告）日：2004-02-18
• [EN] INHIBITORS OF BACE<br/>[FR] INHIBITEURS DE BACE
  申请人：VERTEX PHARMA

  公开号：WO2002088101A2

  公开（公告）日：2002-11-07

  The present invention relates to inhibitors of aspartic proteinases, particularly, BACE. The present invention also relates to compositions thereof and methods therewith for inhibiting BACE activity in a mammal, and for treating Alzheimer's Disease and other BACE-mediated diseases.
• Synthesis and biological evaluation of piperazine-based derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1)
  作者：Bin Ye、Yuo-Ling Chou、Rushad Karanjawala、Wheeseong Lee、Shou-Fu Lu、Kenneth J. Shaw、Steven Jones、Dao Lentz、Amy Liang、Jih-Lie Tseng、Qingyu Wu、Zuchun Zhao

  DOI：10.1016/j.bmcl.2003.11.035

  日期：2004.2

  Compound 2 was identified by high throughput screening as a novel PAI-1 inhibitor. Systematic optimization of the A, B, and C segments of 2 resulted in the identification of a more potent compound 39 with good oral bioavailability. The synthesis and SAR data are presented in this report. (C) 2003 Elsevier Ltd. All rights reserved.